Is Nitrazepam 4mg/5ml oral suspension a controlled drug in the UK?

Yes, Nitrazepam 4mg/5ml oral suspension is classified as Schedule 4 (CD Benz) under the UK Misuse of Drugs Regulations. This means there are special legal requirements for prescribing, dispensing, and storing this medicine. (Source: NHS dm+d, UK Misuse of Drugs Regulations 2001)

What should I avoid while taking Nitrazepam 4mg/5ml oral suspension?

Avoid alcohol. Limit caffeine intake. Take with food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Nitrazepam 4mg/5ml oral suspension?

Nitrazepam 4mg/5ml oral suspension is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Nitrazepam 4mg/5ml oral suspension?

Nitrazepam 4mg/5ml oral suspension is the generic name. It is available under brand names including: Nitrazepam 4mg/5ml oral suspension. (Source: NHS dm+d — Actual Medicinal Products)

Nitrazepam 4mg/5ml oral suspension

Prescription only

Requires a prescription from a doctor or prescriber

Oral suspension

4mg/5ml

Oral

A benzodiazepine derivative used as an anticonvulsant and hypnotic.

Active ingredients:

Nitrazepam

CD Schedule 4

Minimal controls; includes benzodiazepines and anabolic steroids

details

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.01.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05CD02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Nitrazepam

1 safety notice

Schedule 4

Legal requirements and restrictions

Benzodiazepines and similar medicines. Subject to minimal controlled drug requirements.

Legal requirements

Prescriptions valid for 28 days
No controlled drugs register required
No safe custody requirements
Record keeping requirements for imports/exports

Other medicines in this category

Diazepam, Lorazepam, Nitrazepam, Zolpidem, Zopiclone

View full UK controlled drugs list

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Nitrazepam

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Nitrazepam

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Nitrazepam

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Nitrazepam on the MHRA register

Nitrazepam 4mg/5ml oral suspension

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

5 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Midazolam 500mg/500ml solution for infusion bottles

Infusion

500mg/500ml

Same therapeutic group

Remimazolam 50mg powder for solution for injection vials

Injection

50mg

Same therapeutic group

Midazolam 2.5mg/0.25ml oromucosal solution pre-filled oral syringes sugar free

Other

2.5mg/0.25ml

Same therapeutic group

Midazolam 5mg/0.5ml oromucosal solution pre-filled oral syringes sugar free

Other

5mg/0.5ml

Same therapeutic group

Midazolam 7.5mg/0.75ml oromucosal solution pre-filled oral syringes sugar free

Other

7.5mg/0.75ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Nitrazepam

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

TA77

Technology appraisal

Updated Apr 2004

Epilepsies in children, young people and adults (NG217)

NG217

NICE guideline

Updated Jan 2025

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Nitrazepam

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

12141511000001101

dm+d ID

12141511000001101

VTM (Virtual Therapeutic Moiety)

776924001

VMP (Virtual Medicinal Product)

12141511000001101

BNF code

04010100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05CD02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

15-38 hours

Mechanism

Nitrazepam belongs to a group of medicines called benzodiazepines.

Food interactions

3 warnings

Human targets

4 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

53-94%

Bioavailability is 53-94% following oral administration.

Half-life

15-38 hours

15-38 hours (mean elimination half life 26 hours).

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

A benzodiazepine derivative used as an anticonvulsant and hypnotic.

Properties:

solid

Avg. mass: 281.27 Da

DrugBank indication

Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.

Also known as(81)

1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one

2,3-dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-one

7-nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one

7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one

N-desmethylnimetazepam

Nitrazépam

Nitrazepam

Nitrazepamum

Dosage forms(5)

Tablet, film coated (Oral) — 5 MG

Tablet (Oral) — 10 mg/1

Tablet (Oral)

Tablet (Oral) — 5 mg

Tablet (Oral) — 10 mg

Molecular properties(19)

Drug interactions(909)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Hydrocodone

Moderate

DB00956

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Nitrazepam can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Nitrazepam may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Mirtazapine

Moderate

DB00370

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Orphenadrine

Moderate

DB01173

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Pramipexole

Moderate

DB00413

Nitrazepam may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Nitrazepam may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Nitrazepam may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Nitrazepam.

Check this interaction

Suvorexant

Moderate

DB09034

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Thalidomide

Moderate

DB01041

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Clozapine

Unknown severity

DB00363

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Clozapine.

Check this interaction

Methadone

Moderate

DB00333

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Check this interaction

Sodium oxybate

Moderate

DB09072

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Teduglutide

Unknown severity

DB08900

The serum concentration of Nitrazepam can be increased when it is combined with Teduglutide.

Check this interaction

Yohimbine

Moderate

DB01392

The therapeutic efficacy of Nitrazepam can be increased when used in combination with Yohimbine.

Check this interaction

Mefloquine

Moderate

DB00358

The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.

Check this interaction

Mianserin

Moderate

DB06148

The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mianserin.

Check this interaction

Orlistat

Moderate

DB01083

Orlistat can cause a decrease in the absorption of Nitrazepam resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Topotecan

Moderate

DB01030

Nitrazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Flumazenil

Moderate

DB01205

Flumazenil may decrease the sedative activities of Nitrazepam.

Check this interaction

Rifampin

Unknown severity

DB01045

The serum concentration of Nitrazepam can be decreased when it is combined with Rifampicin.

Check this interaction

Tetracosactide

Unknown severity

DB01284

The serum concentration of Nitrazepam can be increased when it is combined with Tetracosactide.

Check this interaction

Ethanol

Moderate

DB00898

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Seproxetine.

Check this interaction

Fluvoxamine

Unknown severity

DB00176

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluvoxamine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.

Check this interaction

Duloxetine

Unknown severity

DB00476

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.

Check this interaction

Paroxetine

Unknown severity

DB00715

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.

Check this interaction

Sertraline

Unknown severity

DB01104

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.

Check this interaction

Sibutramine

Unknown severity

DB01105

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Sibutramine.

Check this interaction

Escitalopram

Unknown severity

DB01175

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.

Check this interaction

Milnacipran

Unknown severity

DB04896

The risk or severity of adverse effects can be increased when Nitrazepam is combined with Milnacipran.

Check this interaction

Showing 50 of 909 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Caffeine Notice

Limit caffeine intake.

Take With Food

Take with food.

Toxicity & overdose

An overdose of nitrazepam may lead to impaired breathing, dizziness, decreased cognition and balance, bluish nails and lips, slurred speech, and extreme somnolence, among others. In severe overdose, these symptoms may progress to a coma with a possibility of death.

How it works

Mechanism of action

Nitrazepam belongs to a group of medicines called benzodiazepines. This drug affects central benzodiazepine receptors, which are associated with inhibitory GABA (gamma amino butyric acid)receptors, leading to enhanced GABA binding activity. GABA is a major neurotransmitter in the brain, which causes somnolence, relaxation of muscles, a decrease in anxiety and general central nervous system depression. Nitrazepam has anticonvulsant properties that may be attributed to its ability to bind to voltage-dependent sodium channels. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.

Pharmacodynamics

Nitrazepam is a type of benzodiazepine drug. It is a powerful hypnotic drug which possesses strong sedative, anxiolytic, amnestic, anticonvulsant, and skeletal muscle relaxant properties. Nitrazepam shortens the time required to fall asleep and lengthens the duration of sleep. It is also useful for the management of myoclonic seizures.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Bioavailability is 53-94% following oral administration.

Half-life

15-38 hours (mean elimination half life 26 hours).

Drug targets(4)

Proteins and enzymes this drug interacts with in the body

Gamma-aminobutyric acid receptor subunit theta

BE0004797

GABRQ

positive allosteric modulator

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Theta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:10449790 PMID:16412217
GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient PMID:10449790 PMID:16412217

Gamma-aminobutyric acid receptor subunit gamma-3

BE0008668

GABRG3

ligand

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (By similarity). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride across the cell membrane down their electrochemical gradient (By similarity)

Gamma-aminobutyric acid receptor subunit alpha-1

BE0000795

GABRA1

antagonist

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:23909897 PMID:25489750 PMID:29950725 PMID:30602789

GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) .
PMID:29950725 PMID:30602789
When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient .
PMID:23909897 PMID:29950725 PMID:30602789

Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation .
PMID:23909897 PMID:25489750
GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity).

GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity)

Sodium channel protein type 1 subunit alpha

BE0000141

SCN1A

other/unknown

Specific functionvoltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential

Cellular location

Cell membrane

General function & pharmacology

Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:14672992
By regulating the excitability of neurons, ensures that they respond appropriately to synaptic inputs, maintaining the balance between excitation and inhibition in brain neural circuits (By similarity). Nav1.1 plays a role in controlling the excitability and action potential propagation from somatosensory neurons, thereby contributing to the sensory perception of mechanically-induced pain (By similarity)

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

CYP2E1Cytochrome P450 2E1

inhibitor

Scientific references(5)

Rickels K.

The clinical use of hypnotics: indications for use and the need for a variety of hypnotics.

Acta Psychiatrica Scandinavica

198674(S332):132-141. doi: 10.1111/j.1600-0447.1986.tb08990.x

PMID: 2883820 DOI: 10.1111/j.1600-0447.1986.tb08990.x

Robertson M.D., Drummer O.H.

Postmortem Drug Metabolism by Bacteria.

Journal of Forensic Sciences

199540(3):382-386. doi: 10.1520/jfs13791j

PMID: 7782744 DOI: 10.1520/jfs13791j

Oelschlager H.

Chemical models of vitrinite reflectance evolution.

Geologische Rundschau

198978(1):349-359. doi: 10.1007/bf01988369

PMID: 2570451 DOI: 10.1007/bf01988369

Podhorna J., Krsiak M.

Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice.

Behavioural Pharmacology

200011(2):143-151. doi: 10.1097/00008877-200004000-00006

PMID: 10877119 DOI: 10.1097/00008877-200004000-00006

Nowakowska E., Chodera A.

Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats.

Pharmacology Biochemistry and Behavior

199138(2):265-266. doi: 10.1016/0091-3057(91)90276-8

PMID: 1676167 DOI: 10.1016/0091-3057(91)90276-8

ATC classification(1 code)

ATC N05CD02

Affected organisms(1)

Humans and other mammals

International brands(37)

Experimental properties(3)

Commercial products(10)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Nitrazepam

DB01595

CAS number

146-22-5

UNII (FDA)

9CLV70W7HS

InChI Key (molecular fingerprint)

KJONHKAYOJNZEC-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

9558

ChEBI

7581

PubChem Compound

4506

PubChem Substance

46505806

KEGG Compound

C07487

KEGG Drug

D00531

ChemSpider

4350

BindingDB

50020856

PharmGKB

PA10242

Therapeutic Targets Database

DAP000691

Wikipedia

Nitrazepam

ChEMBL

CHEMBL13209

ZINC

ZINC000004311748

RxCUI

7440

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10585

GenAtlas

SCN1A

GeneCards

SCN1A

GenBank Gene Database

AF225985

GenBank Protein Database

12642270

IUPHAR

578

Guide to Pharmacology

578

UniProtKB

P35498

UniProt Accession

SCN1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

International reference pricing

8 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.08/tablet

To $0.24/tablet

Nitrazadon 5 mg Tablet

$0.08/tablet

Sandoz Nitrazepam 5 mg Tablet

$0.08/tablet

Apo-Nitrazepam 5 mg Tablet

$0.09/tablet

Nitrazadon 10 mg Tablet

$0.11/tablet

Sandoz Nitrazepam 10 mg Tablet

$0.11/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Nitrazepam 4mg/5ml oral suspension

Legal requirements

Other medicines in this category

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Clinical essentials

Pharmacology

Deep science
6

Chemical identifiers

Nitrazepam

Additional database identifiers

International reference pricing

DrugBank citations

Nitrazepam 4mg/5ml oral suspension

Controlled drug information

Legal requirements

Other medicines in this category

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Clinical essentials

Pharmacology

Deep science6

Chemical identifiers

Nitrazepam

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
6